419 related articles for article (PubMed ID: 33388021)
1. A Systematic Review of the MDMA Model to Address Social Impairment in Autism.
Chaliha D; Mamo JC; Albrecht M; Lam V; Takechi R; Vaccarezza M
Curr Neuropharmacol; 2021; 19(7):1101-1154. PubMed ID: 33388021
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism.
Chaliha D; Albrecht M; Vaccarezza M; Takechi R; Lam V; Al-Salami H; Mamo J
Dev Neurosci; 2020; 42(1):12-48. PubMed ID: 32810856
[TBL] [Abstract][Full Text] [Related]
3. Effects of MDMA on attention to positive social cues and pleasantness of affective touch.
Bershad AK; Mayo LM; Van Hedger K; McGlone F; Walker SC; de Wit H
Neuropsychopharmacology; 2019 Sep; 44(10):1698-1705. PubMed ID: 31042696
[TBL] [Abstract][Full Text] [Related]
4. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.
Kamilar-Britt P; Bedi G
Neurosci Biobehav Rev; 2015 Oct; 57():433-46. PubMed ID: 26408071
[TBL] [Abstract][Full Text] [Related]
5. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens.
Rein B; Raymond K; Boustani C; Tuy S; Zhang J; St Laurent R; Pomrenze MB; Boroon P; Heifets B; Smith M; Malenka RC
Sci Adv; 2024 Apr; 10(17):eadl6554. PubMed ID: 38657057
[TBL] [Abstract][Full Text] [Related]
6. Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.
Bedi G; Hyman D; de Wit H
Biol Psychiatry; 2010 Dec; 68(12):1134-40. PubMed ID: 20947066
[TBL] [Abstract][Full Text] [Related]
7. Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy").
Wunderli MD; Vonmoos M; Treichler L; Zeller C; Dziobek I; Kraemer T; Baumgartner MR; Seifritz E; Quednow BB
Int J Neuropsychopharmacol; 2018 Apr; 21(4):333-344. PubMed ID: 29087534
[TBL] [Abstract][Full Text] [Related]
8. MDMA enhances emotional empathy and prosocial behavior.
Hysek CM; Schmid Y; Simmler LD; Domes G; Heinrichs M; Eisenegger C; Preller KH; Quednow BB; Liechti ME
Soc Cogn Affect Neurosci; 2014 Nov; 9(11):1645-52. PubMed ID: 24097374
[TBL] [Abstract][Full Text] [Related]
9. Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA).
Curry DW; Berro LF; Belkoff AR; Sulima A; Rice KC; Howell LL
Neuropharmacology; 2019 Jun; 151():13-20. PubMed ID: 30922893
[TBL] [Abstract][Full Text] [Related]
10. Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice.
Kuteykin-Teplyakov K; Maldonado R
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1773-83. PubMed ID: 25241352
[TBL] [Abstract][Full Text] [Related]
11. Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD.
Walsh JJ; Llorach P; Cardozo Pinto DF; Wenderski W; Christoffel DJ; Salgado JS; Heifets BD; Crabtree GR; Malenka RC
Neuropsychopharmacology; 2021 Oct; 46(11):2000-2010. PubMed ID: 34239048
[TBL] [Abstract][Full Text] [Related]
12. The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?
Bershad AK; Miller MA; Baggott MJ; de Wit H
J Psychopharmacol; 2016 Dec; 30(12):1248-1258. PubMed ID: 27562198
[TBL] [Abstract][Full Text] [Related]
13. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.
Danforth AL; Struble CM; Yazar-Klosinski B; Grob CS
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():237-49. PubMed ID: 25818246
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration.
Aarde SM; Taffe MA
Curr Top Behav Neurosci; 2017; 32():145-164. PubMed ID: 27909988
[TBL] [Abstract][Full Text] [Related]
15. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A; Gonnier V; Aussilloux C
Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
[TBL] [Abstract][Full Text] [Related]
16. Memantine for autism spectrum disorder.
Brignell A; Marraffa C; Williams K; May T
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD013845. PubMed ID: 36006807
[TBL] [Abstract][Full Text] [Related]
17. Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration.
Francis SM; Kirkpatrick MG; de Wit H; Jacob S
Psychoneuroendocrinology; 2016 Dec; 74():92-100. PubMed ID: 27592327
[TBL] [Abstract][Full Text] [Related]
18. Ketamine administration in early postnatal life as a tool for mimicking Autism Spectrum Disorders core symptoms.
Bove M; Schiavone S; Tucci P; Sikora V; Dimonte S; Colia AL; Morgese MG; Trabace L
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110560. PubMed ID: 35460811
[TBL] [Abstract][Full Text] [Related]
19. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD).
Elliott SJ; Marshall D; Morley K; Uphoff E; Kumar M; Meader N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013173. PubMed ID: 34693989
[TBL] [Abstract][Full Text] [Related]
20. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism.
Watanabe T; Kuroda M; Kuwabara H; Aoki Y; Iwashiro N; Tatsunobu N; Takao H; Nippashi Y; Kawakubo Y; Kunimatsu A; Kasai K; Yamasue H
Brain; 2015 Nov; 138(Pt 11):3400-12. PubMed ID: 26336909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
